RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

  • RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors.
  • Craig-Hallum’s 22nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series of one-on-one meetings with investors.

A live webcast of the RBC conference presentation will be accessible through Repligen’s  website at , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at , and follow us on .

Repligen Contact:

Jacob Johnson

VP, Investor Relations

(781) 419-0204



EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation to Present at Upcoming May Investor Conferences WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investo...

 PRESS RELEASE

Repligen Reports First Quarter 2025 Financial Results

Repligen Reports First Quarter 2025 Financial Results Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period en...

 PRESS RELEASE

Repligen to Report First Quarter 2025 Financial Results

Repligen to Report First Quarter 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessi...

 PRESS RELEASE

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen Appoints Jacob Johnson As Vice President Investor Relations WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garlan...

 PRESS RELEASE

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and . (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch